AbbVie Financial Statements From 2010 to 2024
| 4AB Stock | EUR 173.96 1.94 1.10% |
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as , as well as many indicators such as . AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
AbbVie |
AbbVie Inc Company Current Valuation Analysis
AbbVie's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AbbVie Current Valuation | 331.38 B |
Most of AbbVie's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AbbVie Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AbbVie Inc has a Current Valuation of 331.38 B. This is much higher than that of the Healthcare sector and 82.21% higher than that of the Drug Manufacturers - Major industry. The current valuation for all Germany stocks is significantly lower than that of the firm.
AbbVie Inc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AbbVie's current stock value. Our valuation model uses many indicators to compare AbbVie value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AbbVie competition to find correlations between indicators driving AbbVie's intrinsic value. More Info.AbbVie Inc is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.14 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AbbVie Inc is roughly 7.30 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AbbVie's earnings, one of the primary drivers of an investment's value.About AbbVie Financial Statements
AbbVie stakeholders use historical fundamental indicators, such as AbbVie's revenue or net income, to determine how well the company is positioned to perform in the future. Although AbbVie investors may analyze each financial statement separately, they are all interrelated. For example, changes in AbbVie's assets and liabilities are reflected in the revenues and expenses on AbbVie's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in AbbVie Inc. Please read more on our technical analysis and fundamental analysis pages.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. ABBVIE INC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 30000 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in AbbVie Stock
When determining whether AbbVie Inc is a strong investment it is important to analyze AbbVie's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AbbVie's future performance. For an informed investment choice regarding AbbVie Stock, refer to the following important reports:Check out the analysis of AbbVie Correlation against competitors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.